Table 4 Top 5 most frequent regimens during first-, second-, and third-line therapy
First-line therapy | n (%) | Second-line therapy | n (%) | Third-line therapy | n (%) |
|---|---|---|---|---|---|
All patients (N = 1227) | All patients (N = 476) | All patients (N = 189) | |||
Docetaxel–gemcitabine | 325 (26.5) | Doxorubicin | 101 (21.2) | Doxorubicin | 28 (14.8) |
Doxorubicin | 231 (18.8) | Docetaxel–gemcitabine | 83 (17.4) | Docetaxel–gemcitabine | 21 (11.1) |
Gemcitabine | 112 (9.1) | Gemcitabine | 41 (8.6) | Gemcitabine | 21 (11.1) |
Paclitaxel | 68 (5.5) | Paclitaxel | 21 (4.4) | Ifosfamide | 15 (7.9) |
Bevacizumab | 41 (3.3) | Ifosfamide | 20 (4.2) | Dacarbazine | – |
Leiomyosarcomas (N = 341) | Leiomyosarcomas (N = 148) | Leiomyosarcomas (N = 66) | |||
|---|---|---|---|---|---|
Docetaxel–gemcitabine | 136 (39.9) | Doxorubicin | 41 (27.7) | Doxorubicin | 12 (18.2) |
Doxorubicin | 64 (18.8) | Docetaxel–gemcitabine | 35 (23.7) | Docetaxel–gemcitabine | – |
Gemcitabine | 43 (12.6) | Gemcitabine | – | Gemcitabine | – |
Carboplatin-paclitaxel | – | Docetaxel | – | Carboplatin-paclitaxel | – |
Dacarbazine-doxorubicin | – | Dacarbazine | – | Ifosfamide | – |
Doxorubicin–ifosfamide | – | ||||
Temozolomide | – |
Undifferentiated pleomorphic sarcoma (N = 158) | Undifferentiated pleomorphic sarcoma (N = 64) | Undifferentiated pleomorphic sarcoma (N = 24) | |||
|---|---|---|---|---|---|
Docetaxel–gemcitabine | 36 (22.8) | Docetaxel–gemcitabine | 1 3 (20.3) | Doxorubicin | – |
Doxorubicin | 32 (20.3) | Doxorubicin | – | Docetaxel–gemcitabine | – |
Gemcitabine | 13 (8.2) | Ifosfamide | – | Dacarbazine | – |
Ifosfamide | 11 (7.0) | Gemcitabine | – | Ifosfamide | – |
Doxorubicin–ifosfamide | – | Paclitaxel | – | ||
Temozolomide | – |
Liposarcomas (N = 140) | Liposarcomas (N = 45) | Liposarcomas (N = 15) | |||
|---|---|---|---|---|---|
Doxorubicin | 34 (24.3) | Docetaxel–gemcitabine | 11 (24.4) | Ifosfamide | – |
Docetaxel–gemcitabine | 31 (22.1) | Doxorubicin | – | Gemcitabine | – |
Bevacizumab | 13 (9.3) | Gemcitabine | – | ||
Gemcitabine | 12 (8.6) | Docetaxel-doxorubicin-gemcitabine | – | ||
Doxorubicin–ifosfamide | – | Ifosfamide | – | ||
Ifosfamide | – |
Vascular sarcomas (N = 130) | Vascular sarcomas (N = 60) | Vascular sarcomas (N = 21) | |||
|---|---|---|---|---|---|
Paclitaxel | 52 (40.0) | Doxorubicin | 18 (30.0) | Doxorubicin | – |
Doxorubicin | 22 (16.9) | Paclitaxel | – | Doxorubicin–ifosfamide | – |
Docetaxel–gemcitabine | – | Docetaxel–gemcitabine | – | Docetaxel | – |
Doxorubicin–ifosfamide | – | Gemcitabine | – | Docetaxel–gemcitabine | – |
Docetaxel | – | Docetaxel | – | Paclitaxel | – |
Fibroblastic/Myofibroblastic sarcomas (N = 58) | Fibroblastic/Myofibroblastic sarcomas (N = 19) | Fibroblastic/Myofibroblastic sarcomas (N = –) | |||
|---|---|---|---|---|---|
Docetaxel–gemcitabine | 16 (27.6) | Bevacizumab | – | Docetaxel–gemcitabine | – |
Doxorubicin | – | Docetaxel–gemcitabine | – | Gemcitabine | – |
Bevacizumab | – | Bevacizumab-temozolomide | – | ||
Gemcitabine | – | Gemcitabine | – | ||
Cisplatin | – | Temozolomide | – | ||
Doxorubicin–ifosfamide | – |
Nerve sheath sarcomas (N = 24) | Nerve sheath sarcomas (N = –) | Nerve sheath sarcomas (N = –) | |||
|---|---|---|---|---|---|
Doxorubicin | – | Doxorubicin | – | ||
Docetaxel–gemcitabine | – | ||||
Gemcitabine | – | ||||
Doxorubicin–ifosfamide | – | ||||
Ifosfamide | – |
Rhabdomyosarcomas (N = 28) | Rhabdomyosarcomas (N = 15) | Rhabdomyosarcomas (N = –) | |||
|---|---|---|---|---|---|
Docetaxel–gemcitabine | – | Doxorubicin | – | ||
Carboplatin-paclitaxel | – | Cyclophosphamide-doxorubicin-vincristine | – | ||
Cyclophosphamide-dactinomycin-vincristine | – | ||||
Cyclophosphamide-doxorubicin | – | ||||
Cyclophosphamide-doxorubicin-vincristine | – | ||||
Doxorubicin | – |
Synovial sarcomas (N = 21) | Synovial sarcomas (N = –) | Synovial sarcomas (N = –) | |||
|---|---|---|---|---|---|
Docetaxel–gemcitabine | – | Dacarbazine | – | ||
Doxorubicin | – | Doxorubicin | – | ||
Temozolomide | – | Ifosfamide | – |
Others/NOS (N = 327) | Others/NOS (N = 109) | Others/NOS (N = 46) | |||
|---|---|---|---|---|---|
Docetaxel–gemcitabine | 81 (24.8) | Docetaxel–gemcitabine | 14 (12.8) | Gemcitabine | – |
Doxorubicin | 61 (18.7) | Doxorubicin | 14 (12.8) | Ifosfamide | – |
Gemcitabine | 30 (9.2) | Gemcitabine | 12 (11.0) | Dacarbazine | – |
Carboplatin-paclitaxel | 16 (4.9) | Carboplatin-paclitaxel | – | Docetaxel–gemcitabine | – |
Paclitaxel | 12 (3.7) | Docetaxel | – | Doxorubicin | – |
Doxorubicin–ifosfamide | – | ||||
Ifosfamide | – |